Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary "manifold folding" technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
This development is significant for the pharmaceutical industry, where the average drug takes over a decade and billions of dollars to reach the market. By compressing the timeline from concept to investigational new drug filing to under two years, Oncotelic's PDAOAI platform could potentially reshape drug development economics, making it faster and more cost-effective to bring new therapies to patients, especially in high-unmet-need areas like oncology and rare pediatric indications.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. The company leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. The platform is built on Qdrant, an open-source vector database, and utilizes a vast indexed dataset of approximately 28 million PubMed abstracts to drive discovery.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.
For more information about Oncotelic, visit the company's newsroom at https://ibn.fm/OTLC. The full press release is available at https://ibn.fm/Ce72F.
